VIR-7831 Supply Agreement for Pandemic Purposes
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Procedure | limited |
| OCID | ocds-h6vhtk-02dfcc |
Awards (3)
This procurement was awarded to 2 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| GlaxoSmithKline UK Limited | £1 | 10 Aug 2021 | active |
| GlaxoSmithKline UK Limited | · | · | active |
| GLAXOSMITHKLINE UK LIMITED | £1 | 10 Aug 2021 | active |
description
The evolution of the UK’s pandemic response has highlighted the critical importance and economic value of a multi-layered and comprehensive approach to COVID-19.The need for antibodies and other therapeutics has always been under consideration, the mutation of the virus and the risk this poses on antibody and vaccine efficacy has only recently been properly identified and still requires further academic studies.These unforeseen circumstances mean there is now a critical, urgent need to procure and deploy a new class of mAbs, that can neutralise any COVID-19 variant. These neutralising mAbs provide protection to a cohort of the population who, for medical reasons, cannot mount an appropriate immune response to vaccination or, for whatever reason, do not get vaccinated and are also at higher risk of hospitalisation or death.This agreement is for the procurement of 100,008 units of Sotrovimab (VIR-7831).
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 13 Sept 2021 | Contract award notice (F03) | Earlier regulations | 022621-2021 |
| 15 Nov 2022 | Award (award) | · | 38d642fb-7004-4ea2-b03e-cc4ca9026c00-590251 |
more from Department of Health and Social Care
- DHSC: Fin: Interim Senior Financial Accountant · £94,250 · 29 Jul 2026
- DHSC: Fin: Interim Financial Accountant · £66,400 · 29 Jul 2026
- DHSC Sinogo claim legal support · £100,000 · 22 Jul 2026
- National Institute for Health and Care Research (NIHR) pre-action letter advice · £80,000 · 22 Jul 2026
- DHSC: ASC: Waves 3 – 5 of the Adult Social Care Workforce Employee Survey · 15 Jul 2026
- Hugh's Report - MH Impact of Life-Threatening Child Illness on Families 2026 · 26 Jun 2026
- Library Mgmt and Enquiry System, E-Archive · £22,578 · 22 Jun 2026
- DHSC: Leeds Maternity Review legal services · £432,000 · 22 Jun 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.